TrialNature medicine2024

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.

Andreas H Diacon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.